Literature DB >> 29503837

Brain Natriuretic Peptides in Screening of Syncope with Cardiac Origin; a Commentary.

Hamideh Feiz Disfani1, Mostafa Kamandi2, Kazem Rahmani3.   

Abstract

Entities:  

Year:  2018        PMID: 29503837      PMCID: PMC5827044     

Source DB:  PubMed          Journal:  Emerg (Tehran)        ISSN: 2345-4563


× No keyword cloud information.
Dear Editor: Syncope is a serious problem with life-time prevalence of 35% (1). It is estimated that 1 -3% of referrals to emergency departments and in-patient admissions are due to syncope (2). The underlying conditions can be cardiac or neurologic. Considering the completely different circumstances ruling the encounters with cardiac and neurologic syncope, in recent years many attempts have been made to find the proper tool for differentiating cardiac and non-cardiac causes of syncope. The result of which is formation of some clinical decision rules including San Francisco Syncope Rule (SFSR), Osservatorio Epidemiologico sulla Sincope nel Lazio (OESIL), Evaluation of Guidelines in Syncope Study (EGSYS), risk stratification of syncope in the emergency department (Rose), and Boston Syncope Rules The serum marker brain natriuretic peptide (BNP), which is becoming increasingly established in emergency departments for diagnosis of acute heart failure, can reflect the presence of a structural heart disease (3-5). It seems that BNP could be considered as a screening tool in detection of syncope with cardiac origin. In a study by Wójtowicz J et al. who evaluated BNP in children and adolescents with syncope, there was no significant difference in terms of BNP level between the syncope and control groups (6). In contrast, Zhang Q et al. concluded that serum BNP is helpful in differentiating cardiac (958.78 ± 2443.41 pg/mL) and non-cardiac (31.05 ± 22.64 pg/mL) syncope (7). Tanimoto K et al. considered the cut-off value of 40 pg/ml for BNP in differentiating cardiac and non-cardiac syncope and found that it had 82% sensitivity and 92% specificity (8). A significant difference was observed in BNP level of the cardiac group (514 pg/ml) compared to the non-cardiac ones (182 pg/ml) in Pfister et al. study (4). It seems that, more research is needed to clarify this relationship and the variables that might play the role of confounders in a causal inference. More studies on children are required because there is some controversy regarding this relationship. Running studies with accurate methodology, large sample sizes, and in a multi-centric fashion could be helpful in this regard.
  8 in total

1.  Significance and utility of plasma brain natriuretic peptide concentrations in patients with idiopathic ventricular arrhythmias.

Authors:  Hiroshi Tada; Sachiko Ito; Goro Shinbo; Kazuyoshi Tadokoro; Itaru Ito; Tohru Hashimoto; Kohei Miyaji; Kenichi Kaseno; Shigeto Naito; Akihiko Nogami; Shigeru Oshima; Koichi Taniguchi
Journal:  Pacing Clin Electrophysiol       Date:  2006-12       Impact factor: 1.976

2.  Predictors of elevated NT-pro-BNP in cardiovascular patients without acute heart failure.

Authors:  Roman Pfister; Dajana Tan; Jaimy Thekkanal; Martin Hellmich; Chistian Alfons Schneider
Journal:  Int J Cardiol       Date:  2007-10-25       Impact factor: 4.164

3.  Natriuretic peptides in the evaluation of syncope in children and adolescents.

Authors:  Jerzy Wójtowicz; Wojciech Szczepański; Aleksandra Bogdan; Marcin Baran; Julianna Szczurak; Artur Bossowski
Journal:  Scand J Clin Lab Invest       Date:  2014-02-24       Impact factor: 1.713

4.  Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years.

Authors:  Karin S Ganzeboom; Gideon Mairuhu; Johannes B Reitsma; Mark Linzer; Wouter Wieling; Nynke van Dijk
Journal:  J Cardiovasc Electrophysiol       Date:  2006-11

5.  NT-pro-BNP for differential diagnosis in patients with syncope.

Authors:  Giorgio Costantino; Monica Solbiati; Giuseppina Pisano; Raffaello Furlan
Journal:  Int J Cardiol       Date:  2008-08-08       Impact factor: 4.164

Review 6.  Epidemiology of syncope/collapse in younger and older Western patient populations.

Authors:  Rose Anne Kenny; Jaspreet Bhangu; Bellinda L King-Kallimanis
Journal:  Prog Cardiovasc Dis       Date:  2013 Jan-Feb       Impact factor: 8.194

7.  Diagnostic value of serum brain natriuretic peptide in syncope in children and adolescents.

Authors:  Qingyou Zhang; Hongfang Jin; Jianguang Qi; Hui Yan; Junbao Du
Journal:  Acta Paediatr       Date:  2013-02-21       Impact factor: 2.299

8.  Usefulness of brain natriuretic peptide as a marker for separating cardiac and noncardiac causes of syncope.

Authors:  Kojiro Tanimoto; Kazushi Yukiiri; Katsufumi Mizushige; Yuichiro Takagi; Hisashi Masugata; Kaori Shinomiya; Naohisa Hosomi; Tsutomu Takahashi; Koji Ohmori; Masakazu Kohno
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.